title: [Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
abstract: Data are presented on a randomized study (stage II) which was undertaken to assess the efficacy of neoadjuvant chemotherapy (doxorubicin+paclitaxel) vis-a-vis endocrine therapy with aromatase inhibitors (anastrazole or exemestane) in postmenopausal women with ER-positive and/or PgR-positive tumors. Preoperative neoadjuvant chemotherapy was well tolerated and showed similar rates of overall response as compared with the latter regimen.
authors.forename: V F
authors.initials: VF
authors.lastname: Semiglazov
authors.forename: V V
authors.initials: VV
authors.lastname: Semiglazov
authors.forename: G A
authors.initials: GA
authors.lastname: Dashian
authors.forename: E K
authors.initials: EK
authors.lastname: Zhil'tsova
authors.forename: V G
authors.initials: VG
authors.lastname: Ivanov
authors.forename: A A
authors.initials: AA
authors.lastname: Bozhok
authors.forename: E E
authors.initials: EE
authors.lastname: Tonuzov
authors.forename: R M
authors.initials: RM
authors.lastname: Paltuev
authors.forename: O A
authors.initials: OA
authors.lastname: Mel'nikova
authors.forename: A A
authors.initials: AA
authors.lastname: Klettsel'
authors.forename: P V
authors.initials: PV
authors.lastname: Krivorot'ko
authors.forename: R V
authors.initials: RV
authors.lastname: Donskikh
authors.forename: I A
authors.initials: IA
authors.lastname: Kochetova
authors.forename: A O
authors.initials: AO
authors.lastname: Damenia
authors.forename: K Iu
authors.initials: KIu
authors.lastname: Zernov
authors.forename: D A
authors.initials: DA
authors.lastname: Voskresenskiĭ
authors.forename: L M
authors.initials: LM
authors.lastname: Bershteĭn
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000077384:Anastrozole; D000730:Androstadienes / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008327:Mammography; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009570:Nitriles / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014230:Triazoles; D000077384:Anastrozole; D004317:Doxorubicin; C056516:exemestane; D017239:Paclitaxel